Nektar Therapeutics (NKTR) Posts Q2 EPS Loss of $0.32, Revenues 60% Y/Y
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq retreat from record highs as yields and oil climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $39.17 -1.85%
EPS Growth %: -213.5%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
AEHR, VFS, CMTL, More
EPS Growth %: -213.5%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
AEHR, VFS, CMTL, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.32), $0.01 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $17.3 million versus the consensus estimate of $14.89 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi reiterates buy rating on Nektar Therapeutics with $151 target
- Nektar presents early biomarker data for eczema drug at EADV 2026
- McCormick & Co. (MKC) Tops Q3 EPS by 10c, Beats on Revenue; Offers EPS Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
